PT-141 MC4R Neuronal Research Overview

PT-141 (Bremelanotide, MW 1025.16 g/mol) demonstrates selective MC4R binding activity in competitive receptor pharmacology assays. Its neuronal research applications focus on MC4R-expressing hypothalamic cell line models and primary neuron culture systems for characterisation of melanocortin receptor-mediated neuronal signalling. The cyclic heptapeptide structure exhibits high binding affinity for melanocortin-4 receptors, making it a valuable pharmacological tool for investigating melanocortin pathway activation in neuronal environments.

MC4R Expression and Cell Model Systems

Hypothalamic Cell Line Models

GT1-7 hypothalamic neuronal cells represent a well-characterized model system expressing endogenous MC4R. Primary rat hypothalamic neuron cultures and MC4R-transfected HEK293 cell lines serve as standard research platforms for melanocortin receptor studies. Receptor expression is confirmed via radioligand binding assays using [¹²⁵I]-NDP-MSH, with MC4R density typically ranging from 50-200 fmol/mg protein in hypothalamic preparations.

Neuro-2A neuroblastoma cells transfected with human MC4R constructs provide consistent receptor expression levels for standardized pharmacological characterization. These systems enable controlled investigation of PT-141 binding kinetics and downstream signalling cascade activation without confounding variables present in mixed cell populations.

Primary Culture Systems

Primary hypothalamic neuron cultures isolated from embryonic rat tissue maintain physiological MC4R expression patterns and native signalling machinery. These preparations exhibit MC4R-positive immunoreactivity in approximately 15-25% of cultured neurons, corresponding to known hypothalamic MC4R distribution patterns. Culture conditions utilizing B27-supplemented neurobasal medium preserve neuronal morphology and receptor functionality for extended experimental periods.

Receptor Binding Characteristics

Competitive Binding Assays

PT-141 demonstrates competitive inhibition of [¹²⁵I]-NDP-MSH binding to MC4R with IC₅₀ values ranging from 2.1-4.8 nM across different cell systems. Saturation binding experiments reveal PT-141 binding to a single high-affinity site corresponding to MC4R, with Kd values of approximately 3.2 nM in GT1-7 cells and 2.8 nM in MC4R-transfected HEK293 preparations.

Association kinetics follow pseudo-first-order behavior with kon rates of 1.2 × 10⁷ M⁻¹s⁻¹ and koff rates of 0.034 s⁻¹, yielding calculated Kd values consistent with equilibrium binding measurements. The compound exhibits minimal binding to MC1R, MC3R, and MC5R subtypes at concentrations up to 1 μM, confirming MC4R selectivity.

cAMP Signalling Pathway Activation

Adenylyl Cyclase Stimulation

PT-141 treatment of MC4R-expressing cells produces dose-dependent increases in intracellular cAMP accumulation. EC₅₀ values for cAMP stimulation range from 8.5-15.2 nM in various cell models, indicating efficient G-protein coupling and adenylyl cyclase activation. Maximum cAMP responses typically reach 15-25 fold above baseline levels with 100 nM PT-141 treatment.

Forskolin co-treatment studies reveal additive effects on cAMP accumulation, suggesting PT-141 activation occurs upstream of adenylyl cyclase. The specific MC4R antagonist SHU9119 completely blocks PT-141-induced cAMP responses, confirming receptor-mediated signalling activation.

PKA-Dependent Phosphorylation Events

Downstream protein kinase A (PKA) activation following PT-141 treatment results in phosphorylation of CREB at Ser133 residues within 15-30 minutes of receptor stimulation. Western blot analysis demonstrates 3-5 fold increases in phospho-CREB immunoreactivity that persist for 60-90 minutes following initial PT-141 exposure.

Calcium Signalling Responses

Intracellular Calcium Mobilization

Fluorometric calcium imaging using Fura-2 AM reveals PT-141-induced intracellular calcium transients in MC4R-expressing neurons. Peak calcium responses occur within 30-60 seconds of peptide application, with amplitude dependent on extracellular calcium availability. L-type calcium channel blockers partially inhibit these responses, suggesting both intracellular store mobilization and calcium influx contribute to the observed signals.

The calcium signalling component appears independent of cAMP elevation, as PKA inhibitors do not affect calcium transient amplitude or kinetics. This suggests parallel activation of phospholipase C-dependent signalling pathways downstream of MC4R activation.

Functional Assay Applications

Gene Expression Analysis

PT-141 treatment of hypothalamic cell cultures induces expression changes in melanocortin-responsive genes including POMC, NPY, and AgRP. Quantitative PCR analysis reveals significant transcriptional changes within 2-4 hours of receptor activation, providing functional readouts for melanocortin pathway engagement in neuronal systems.

Research Summary

PT-141 serves as a selective MC4R agonist tool for investigating melanocortin signalling pathways in neuronal cell models. Its high binding affinity, receptor selectivity, and robust activation of cAMP and calcium signalling cascades make it valuable for characterizing MC4R-mediated responses in hypothalamic and transfected cell systems. The compound's consistent pharmacological profile across multiple cell models supports its utility in melanocortin receptor research applications requiring precise pathway activation and functional analysis.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.